The Senate Finance Committee released a draft bill that would create a new program within Medicare aimed at incentivizing hospitals, group purchasing organizations (GPOs) and other drug supply chain stakeholders to help create stable pricing for generic drug manufacturers by rewarding quality, reliability and long-term sustainable contracts.